<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>About CDKL5 Deficiency Disorder - Symptoms, Diagnosis & Treatment</title>
    <meta name="description" content="Learn about CDKL5 Deficiency Disorder (CDD), a rare genetic epilepsy affecting 1 in 40,000 births. Understand causes, diagnosis, symptoms, and why gene therapy offers hope.">
    <link rel="stylesheet" href="css/style.css">
    <link rel="stylesheet" href="css/colors.css">
    <style>
        /* Page Container */
        .cdkl5-info-container {
            max-width: 900px;
            margin: 0 auto;
            padding: 3rem 1.5rem;
            background: var(--bg-page);
        }
        
        /* Page Header */
        .cdkl5-info-header {
            text-align: center;
            margin-bottom: 3rem;
        }
        .cdkl5-info-title {
            font-size: 2.5rem;
            color: var(--heading-primary);
            margin-bottom: 1rem;
            font-weight: 700;
            line-height: 1.2;
        }
        .cdkl5-info-subtitle {
            font-size: 1.2rem;
            color: #666;
            max-width: 700px;
            margin: 0 auto;
            line-height: 1.6;
        }
        
        /* Content Sections */
        .cdkl5-section {
            background: white;
            padding: 2.5rem;
            margin-bottom: 2rem;
            border-radius: 12px;
            box-shadow: 0 2px 8px rgba(0,0,0,0.08);
        }
        .cdkl5-section h2 {
            font-size: 2rem;
            color: var(--heading-secondary);
            margin-bottom: 1.5rem;
            padding-bottom: 0.75rem;
            border-bottom: 3px solid var(--accent-primary);
        }
        .cdkl5-section h3 {
            font-size: 1.5rem;
            color: var(--heading-tertiary);
            margin-top: 2rem;
            margin-bottom: 1rem;
        }
        .cdkl5-section p {
            font-size: 1.05rem;
            line-height: 1.8;
            color: #333;
            margin-bottom: 1.25rem;
        }
        .cdkl5-section ul {
            margin: 1rem 0 1.5rem 1.5rem;
            line-height: 1.8;
        }
        .cdkl5-section li {
            margin-bottom: 0.75rem;
            color: #333;
            font-size: 1.05rem;
        }
        .cdkl5-section strong {
            color: var(--text-emphasis);
        }
        
        /* Highlight Box */
        .highlight-box {
            background: linear-gradient(135deg, #fff3e0 0%, #ffe0b2 100%);
            border-left: 4px solid var(--accent-primary);
            padding: 1.5rem 2rem;
            margin: 2rem 0;
            border-radius: 0 8px 8px 0;
        }
        .highlight-box p {
            margin-bottom: 0;
            font-size: 1.1rem;
            color: #555;
        }
        
        /* Stats Box */
        .stats-box {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 1.5rem;
            margin: 2rem 0;
        }
        .stat-item {
            background: linear-gradient(135deg, #e8eaf6 0%, #c5cae9 100%);
            padding: 1.5rem;
            border-radius: 12px;
            text-align: center;
        }
        .stat-number {
            font-size: 2rem;
            font-weight: 700;
            color: var(--heading-secondary);
            margin-bottom: 0.5rem;
        }
        .stat-label {
            font-size: 0.95rem;
            color: #555;
            font-weight: 600;
        }
        
        /* Info Box (for diagnosis codes, etc) */
        .info-box {
            background: linear-gradient(135deg, #f7f6fd 0%, #e8eaf6 100%);
            border: 2px solid #7c4dff;
            border-radius: 12px;
            padding: 1.5rem 2rem;
            margin: 2rem 0;
        }
        .info-box h4 {
            color: #5e35b1;
            font-size: 1.2rem;
            margin-bottom: 1rem;
        }
        .info-box ul {
            margin: 0;
            padding-left: 1.5rem;
        }
        .info-box li {
            color: #555;
        }
        
        /* Call to Action */
        .cdkl5-cta {
            background: linear-gradient(135deg, #ff6600 0%, #ff8c00 100%);
            color: white;
            padding: 3rem 2.5rem;
            border-radius: 12px;
            text-align: center;
            margin-top: 3rem;
            box-shadow: 0 4px 16px rgba(255, 102, 0, 0.3);
        }
        .cdkl5-cta h3 {
            color: white;
            font-size: 2rem;
            margin-bottom: 1rem;
        }
        .cdkl5-cta p {
            font-size: 1.2rem;
            margin-bottom: 2rem;
            opacity: 0.95;
        }
        .cta-button {
            display: inline-block;
            background: white;
            color: #ff6600;
            padding: 1rem 3rem;
            font-size: 1.2rem;
            font-weight: 700;
            border-radius: 50px;
            text-decoration: none;
            transition: transform 0.3s, box-shadow 0.3s;
            box-shadow: 0 4px 12px rgba(0,0,0,0.2);
        }
        .cta-button:hover {
            transform: translateY(-2px);
            box-shadow: 0 6px 20px rgba(0,0,0,0.3);
        }
        
        /* Mobile Responsive */
        @media (max-width: 768px) {
            .cdkl5-info-container {
                padding: 2rem 1rem;
            }
            .cdkl5-info-title {
                font-size: 2rem;
            }
            .cdkl5-section {
                padding: 1.5rem;
            }
            .cdkl5-section h2 {
                font-size: 1.6rem;
            }
            .cdkl5-section h3 {
                font-size: 1.3rem;
            }
            .stats-box {
                grid-template-columns: 1fr;
            }
            .cdkl5-cta {
                padding: 2rem 1.5rem;
            }
            .cdkl5-cta h3 {
                font-size: 1.6rem;
            }
        }
    </style>
</head>
<body>
    <div data-include="inc/header.html"></div>
    
    <main class="cdkl5-info-container">
        <!-- Page Header -->
        <div class="cdkl5-info-header">
            <h1 class="cdkl5-info-title">About CDKL5 Deficiency Disorder</h1>
            <p class="cdkl5-info-subtitle">Understanding the rare genetic condition affecting thousands of children worldwide and why gene therapy offers real hope for a cure.</p>
        </div>
        
        <!-- What is CDKL5? -->
        <section class="cdkl5-section">
            <h2>What is CDKL5 Deficiency Disorder?</h2>
            <p>CDKL5 Deficiency Disorder (CDD) is a rare and severe developmental and epileptic encephalopathy (DEE) caused by pathogenic variants in the CDKL5 gene. It is characterized by early-onset, treatment-resistant seizures—usually beginning within the first few months of life—accompanied by developmental impairments that can affect movement, cognition, vision, and communication to varying degrees in each individual.</p>
            
            <div class="stats-box">
                <div class="stat-item">
                    <div class="stat-number">1 in 40,000</div>
                    <div class="stat-label">Estimated prevalence worldwide</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">First Months</div>
                    <div class="stat-label">Seizures typically begin</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">2004</div>
                    <div class="stat-label">CDKL5 gene identified</div>
                </div>
            </div>
            
            <p>Although classified as a rare disease, CDD is one of the more common single-gene causes of epilepsy, with an estimated prevalence of 1 in 40,000–60,000 live births worldwide.</p>
            
            <h3>The Role of the CDKL5 Gene</h3>
            <p>The CDKL5 gene encodes cyclin-dependent kinase-like 5, a serine/threonine protein kinase that plays a crucial role in neuronal maturation, synaptic signaling, and brain development. The CDKL5 protein modifies other proteins through phosphorylation, a process essential for normal neuronal communication and brain function. While researchers have identified several potential downstream targets, the precise molecular mechanisms that link CDKL5 loss to the neurological symptoms of CDD are still under investigation.</p>
            
            <h3>X-Linked Inheritance</h3>
            <p>The CDKL5 gene is located on the X chromosome (Xp22 region). Because of its X-linked inheritance, CDD primarily affects females, though males can also be affected and typically present with more severe symptoms.</p>
            
            <div class="highlight-box">
                <p><strong>Currently, there are no FDA-approved therapies that address the underlying genetic cause of CDD.</strong> Existing treatments focus on seizure control and supportive care, underscoring the urgent need for disease-modifying treatments such as gene replacement therapy to restore CDKL5 function and improve neurological outcomes.</p>
            </div>
        </section>
        
        <!-- What Causes CDKL5? -->
        <section class="cdkl5-section">
            <h2>What Causes CDKL5 Deficiency Disorder?</h2>
            <p>CDD is caused by mutations in the CDKL5 gene, which provides instructions for making the CDKL5 protein—a kinase essential for normal brain development and function. When the gene is mutated, there is too little or nonfunctional CDKL5 protein, disrupting brain development and leading to seizures and global developmental delay.</p>
            
            <h3>Types of CDKL5 Mutations</h3>
            <p>Mutations in CDKL5 are diverse but generally lead to a loss of protein function. Common types include:</p>
            <ul>
                <li><strong>Missense mutations:</strong> A single DNA change alters one amino acid in the protein.</li>
                <li><strong>Nonsense mutations:</strong> Introduce an early "stop" signal, creating a shortened (truncated) protein.</li>
                <li><strong>Frameshift mutations:</strong> Insertions or deletions that shift the reading frame, usually abolishing protein function.</li>
                <li><strong>Deletions or truncations:</strong> Remove larger parts of the gene, preventing full protein production.</li>
            </ul>
            <p>These mutations disrupt CDKL5's kinase activity, impairing brain signaling pathways necessary for early neuronal development.</p>
            
            <h3>De Novo and Inherited Mutations</h3>
            <p>Most CDKL5 mutations occur <strong>de novo</strong>—new changes that arise spontaneously in the child, not inherited from either parent. These mutations typically occur by chance in the egg or sperm or soon after conception.</p>
            <p>In rare cases, CDKL5 mutations can be inherited, for example, through maternal mosaicism, where the mother carries the mutation in some of her egg cells. Because nearly all cases are de novo, the recurrence risk for siblings is generally very low unless a parent is a mosaic carrier.</p>
            
            <h3>X-Linked Inheritance Pattern</h3>
            <p>CDD follows an X-linked dominant inheritance pattern:</p>
            <ul>
                <li><strong>Females (XX):</strong> Have two X chromosomes; if one carries the CDKL5 mutation, symptoms can range from moderate to severe depending on which X chromosome is active in each cell (a process called X-inactivation).</li>
                <li><strong>Males (XY):</strong> Have only one X chromosome. A single mutation in CDKL5 leads to disease, typically with greater severity because there is no second copy of the gene to compensate.</li>
            </ul>
            
            <h3>Associated Diagnoses</h3>
            <p>Before CDKL5 testing became widely available, children with CDKL5 mutations were often misdiagnosed with other early-onset seizure or developmental disorders, including:</p>
            <ul>
                <li>Infantile spasms (West syndrome)</li>
                <li>Lennox-Gastaut Syndrome (LGS)</li>
                <li>Rett syndrome (early-onset seizure variant)</li>
                <li>Cerebral palsy</li>
                <li>Autism spectrum disorder</li>
                <li>Intractable epilepsy of unknown origin</li>
            </ul>
            <p>These overlaps occur because CDD produces early seizures and developmental delays that resemble other neurological conditions. As genetic testing becomes more accessible, more children are being correctly diagnosed with CDKL5 Deficiency Disorder.</p>
        </section>
        
        <!-- How is it Diagnosed? -->
        <section class="cdkl5-section">
            <h2>How is CDKL5 Deficiency Disorder Diagnosed?</h2>
            <p>CDD is often suspected when a baby or young child develops frequent, treatment-resistant seizures in the first few months of life, along with global developmental delays in motor skills, speech, and cognition. Patients may also have low muscle tone (hypotonia), visual impairment, feeding difficulties, and other neurological symptoms.</p>
            
            <p>Because these symptoms affect multiple developmental areas, early medical records may list a diagnosis of Global Developmental Delay (ICD-10 code F88). Pediatricians and neurologists typically perform a clinical evaluation, review medical history, and order diagnostic tests such as MRI or EEG. When other causes are excluded and the pattern of early-onset seizures and profound delays is present, CDD becomes a strong consideration.</p>
            
            <h3>Genetic Testing</h3>
            <p>A genetic test is required to confirm the diagnosis. The process typically involves:</p>
            <ul>
                <li><strong>Sample collection:</strong> A blood or saliva sample is taken and sent to a specialized laboratory.</li>
                <li><strong>DNA sequencing:</strong> The lab analyzes the child's DNA using an epilepsy gene panel or whole-exome sequencing, which includes CDKL5.</li>
                <li><strong>Interpretation:</strong> Identification of a disease-causing CDKL5 variant confirms the diagnosis.</li>
                <li><strong>Results:</strong> Most labs report results within 2–6 weeks, depending on the test type.</li>
            </ul>
            
            <div class="info-box">
                <h4>ICD-10 Diagnostic Codes</h4>
                <ul>
                    <li><strong>G40.42</strong> – CDKL5 Deficiency Disorder</li>
                    <li><strong>G40.81</strong> – Lennox-Gastaut Syndrome (a seizure pattern that can appear in patients with CDD)</li>
                    <li><strong>F88</strong> – Global Developmental Delay</li>
                </ul>
                <p style="margin-top: 1rem; margin-bottom: 0;">Using these diagnostic codes helps clinicians and families secure appropriate medical support and insurance coverage.</p>
            </div>
        </section>
        
        <!-- Life Expectancy -->
        <section class="cdkl5-section">
            <h2>Life Expectancy and Quality of Life</h2>
            <p>At present (November 2025), there is no published data on life expectancy in CDD. Most available information is anecdotal, shared by families and caregivers through CDKL5 community networks like Facebook groups. Reported outcomes vary widely. While some individuals do not survive beyond childhood due to medical complications, others have lived into adulthood, with cases reported in their 30s and 40s.</p>
            
            <p>CDD is a complex, multisystem disorder, often associated with respiratory challenges, gastrointestinal problems, scoliosis, and sleep disturbances. The emotional, social, and financial burden on families is profound, highlighting the urgent need for effective treatment like gene therapy which can address this disorder at the root cause level.</p>
            
            <div class="highlight-box">
                <p><strong>Note:</strong> As scientific understanding continues to evolve, periodic updates to this content may be necessary to reflect the most current research and clinical knowledge. This article was developed with the assistance of OpenAI's ChatGPT and has been peer reviewed.</p>
            </div>
        </section>
        
        <!-- Call to Action -->
        <div class="cdkl5-cta">
            <h3>Help Us Find a Cure</h3>
            <p>Our AAV9 gene therapy is designed to address CDKL5 Deficiency at its root cause. Your support brings us closer to clinical trials and a potential cure.</p>
            <a href="donate.html" class="cta-button">Donate Now</a>
        </div>
    </main>
    
    <div data-include="inc/footer.html"></div>
    
    <script src="js/includes-loader.js"></script>
</body>
</html>
